Clinical Trial Update: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 pediatric trial evaluating dose-ranging and the efficacy/safety of adding plerixafor to standard mobilization regimens versus standard regimens alone …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Ewing Sarcoma
• Neuroblastoma
• Soft Tissue Sarcoma

Drugs mentioned

• Mozobil (Plerixafor) (Plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma | Phase 1, Phase 2 | Status: COMPLETED